Cellectar biosciences receives european medicines agency priority medicines (prime) designation for iopofosine for waldenstrom's macroglobulinemia

The ema's prime status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options the ema's prime status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options
CLRB Ratings Summary
CLRB Quant Ranking